Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9151437 | 0.98 | L3MBTL1 (0.58) | L3MBTL1HRH3ACACBGRIA2CYP1A2 | |
| SCHEMBL9527993 | 0.95 | L3MBTL1 (0.68) | L3MBTL1HRH3ACACBGRIA2CYP1A2 | |
| SCHEMBL11200681 | 0.87 | L3MBTL1 (0.76) | L3MBTL1HRH3ACACBGRIA2CYP1A2 | |
| SCHEMBL6950745 | 0.83 | L3MBTL1 (0.53) | L3MBTL1HRH3ACACBGRIA2CYP1A2 | |
| SCHEMBL27379105 | 0.81 | L3MBTL1 (0.86) | L3MBTL1HRH3ACACBCYP2C9KCNH2 | |
| SCHEMBL180739 | 0.81 | L3MBTL1 (0.86) | L3MBTL1HRH3ACACBCYP2C9KCNH2 | |
| SCHEMBL7287505 | 0.80 | L3MBTL1 (0.58) | L3MBTL1HRH3LTA4HMAPK1KMT2A | |
| SCHEMBL19717008 | 0.80 | L3MBTL1 (0.67) | L3MBTL1HRH3ACACBGRIA2CYP1A2 | |
| Hydrochloric Acid SCHEMBL6818365 | 0.80 | L3MBTL1 (0.83) | L3MBTL1HRH3ACACBCYP2C9KCNH2 | |
| SCHEMBL10399987 | 0.80 | L3MBTL1 (0.67) | L3MBTL1HRH3ACACBGRIA2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0561898-A1 | NOVEL PROCESS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-09-29 | — | — | EP | claimed |
| WO-1992010499-A1 | NOVEL PROCESS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-06-25 | — | — | WO | claimed |
| WO-2023185821-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2021-08-12 | — | — | US | disclosed |
| EP-3827820-A1 | BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10806717-B2 | Methods and compositions for improving cognitive function | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| EP-0565582-A1 | NOVEL CSAIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-20 | — | — | EP | disclosed |
| EP-0563286-A1 | NOVEL CSAIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-06 | — | — | EP | disclosed |
| EP-0561898-A1 | NOVEL PROCESS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-09-29 | — | — | EP | disclosed |
| WO-1992010190-A1 | NOVEL CSAIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010498-A1 | NOVEL CSAIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010499-A1 | NOVEL PROCESS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-06-25 | — | — | WO | disclosed |
| CN-1051357-A | Be used to produce improving one's methods of diazine piperidine derivative | BRISTOR MYERS SQUIBB CO (US) | 1991-05-15 | — | — | CN | disclosed |
| CN-1051175-A | 1-[[1-[2-(trifluoromethyl)-4-pyrimidyl]-the 4-piperidyl] methyl]-large-scale producing method of 2-Pyrrolidone | BRISTOL MYERS SQUIBB CO (US) | 1991-05-08 | — | — | CN | disclosed |
| US-4963678-A | Process for large-scale production of BMY 21502 | BRISTOL-MYERS SQUIBB CO. (US) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806717-B2 | Methods and compositions for improving cognitive function | GRIN2A, CHRNA2, SYNGR2 | L3MBTL1 4649/4885HRH3 3200/4885ACACB 386/4885 |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | L3MBTL1 4649/4885HRH3 3200/4885ACACB 386/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | L3MBTL1 2648/4885HRH3 4501/4885ACACB 571/4885 |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | L3MBTL1 4165/4885HRH3 3110/4885ACACB 2117/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | L3MBTL1 4649/4885HRH3 3200/4885ACACB 386/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | L3MBTL1 1983/4885HRH3 3993/4885ACACB 1063/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | L3MBTL1 3586/4885HRH3 3606/4885ACACB 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.